Back to search
Alopecia Totalis/Universalis
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Alopecia Totalis/Universalis trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Alopecia Totalis/Universalis trials you may qualify forRationale: Since the introduction of Janus kinase (JAK) inhibitors, there has been a significant advancement in the treatment of pediatric alopecia areata. Elig…
The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of alopecia areata. Alopecia are…
Alopecia Areata (AA) is among the most highly prevalent human autoimmune diseases, leading to disfiguring hair loss due to the collapse of immune privilege of t…
A multicenter prospective registry (STA2R) is conducted to assess systemic treatments for alopecia areata, focusing on effectiveness, safety, and long-term outc…
This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 year…
This study will compare two oral medicines-tofacitinib and methotrexate-for treating severe alopecia areata, including alopecia totalis (loss of all scalp hair)…
Provide pre-approval single patient Expanded Access (compassionate use) of Ritlecitinib for patients.